Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/STEAP2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/STEAP2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/STEAP2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/STEAP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
GO:000689215 | Esophagus | ESCC | post-Golgi vesicle-mediated transport | 82/8552 | 104/18723 | 4.00e-12 | 1.55e-10 | 82 |
GO:009887615 | Esophagus | ESCC | vesicle-mediated transport to the plasma membrane | 99/8552 | 136/18723 | 1.13e-10 | 3.39e-09 | 99 |
GO:000689315 | Esophagus | ESCC | Golgi to plasma membrane transport | 48/8552 | 60/18723 | 5.11e-08 | 9.16e-07 | 48 |
GO:005507617 | Esophagus | ESCC | transition metal ion homeostasis | 87/8552 | 138/18723 | 2.85e-05 | 2.37e-04 | 87 |
GO:00469169 | Esophagus | ESCC | cellular transition metal ion homeostasis | 70/8552 | 115/18723 | 7.28e-04 | 3.79e-03 | 70 |
GO:00550729 | Esophagus | ESCC | iron ion homeostasis | 52/8552 | 85/18723 | 2.86e-03 | 1.21e-02 | 52 |
GO:004819310 | Prostate | BPH | Golgi vesicle transport | 102/3107 | 296/18723 | 3.90e-14 | 4.56e-12 | 102 |
GO:00988768 | Prostate | BPH | vesicle-mediated transport to the plasma membrane | 43/3107 | 136/18723 | 1.11e-05 | 1.51e-04 | 43 |
GO:00550769 | Prostate | BPH | transition metal ion homeostasis | 43/3107 | 138/18723 | 1.66e-05 | 2.07e-04 | 43 |
GO:00068928 | Prostate | BPH | post-Golgi vesicle-mediated transport | 34/3107 | 104/18723 | 4.14e-05 | 4.43e-04 | 34 |
GO:00550727 | Prostate | BPH | iron ion homeostasis | 29/3107 | 85/18723 | 6.22e-05 | 6.23e-04 | 29 |
GO:00469167 | Prostate | BPH | cellular transition metal ion homeostasis | 35/3107 | 115/18723 | 1.64e-04 | 1.42e-03 | 35 |
GO:00068793 | Prostate | BPH | cellular iron ion homeostasis | 21/3107 | 67/18723 | 2.09e-03 | 1.17e-02 | 21 |
GO:00068937 | Prostate | BPH | Golgi to plasma membrane transport | 19/3107 | 60/18723 | 2.94e-03 | 1.54e-02 | 19 |
GO:0006825 | Prostate | BPH | copper ion transport | 7/3107 | 15/18723 | 6.42e-03 | 2.91e-02 | 7 |
GO:004819314 | Prostate | Tumor | Golgi vesicle transport | 105/3246 | 296/18723 | 3.55e-14 | 4.33e-12 | 105 |
GO:005507615 | Prostate | Tumor | transition metal ion homeostasis | 45/3246 | 138/18723 | 9.11e-06 | 1.33e-04 | 45 |
GO:005507213 | Prostate | Tumor | iron ion homeostasis | 31/3246 | 85/18723 | 1.89e-05 | 2.47e-04 | 31 |
GO:000689213 | Prostate | Tumor | post-Golgi vesicle-mediated transport | 35/3246 | 104/18723 | 4.14e-05 | 4.70e-04 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STEAP2 | SNV | Missense_Mutation | rs748899164 | c.157N>A | p.Gly53Ser | p.G53S | Q8NFT2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EY-A2OP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STEAP2 | SNV | Missense_Mutation | rs767925349 | c.62G>A | p.Gly21Asp | p.G21D | Q8NFT2 | protein_coding | deleterious(0.02) | benign(0.229) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STEAP2 | SNV | Missense_Mutation | novel | c.938N>A | p.Ala313Asp | p.A313D | Q8NFT2 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STEAP2 | SNV | Missense_Mutation | novel | c.508N>T | p.Asn170Tyr | p.N170Y | Q8NFT2 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-SL-A6J9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STEAP2 | deletion | Frame_Shift_Del | rs754344704 | c.680delT | p.Phe227SerfsTer9 | p.F227Sfs*9 | Q8NFT2 | protein_coding | | | TCGA-AP-A0LG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STEAP2 | deletion | Frame_Shift_Del | novel | c.1397delN | p.Lys467ArgfsTer23 | p.K467Rfs*23 | Q8NFT2 | protein_coding | | | TCGA-AX-A3G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
STEAP2 | insertion | Nonsense_Mutation | novel | c.1356_1357insGTTGTGTATTAAAGAAATGTGTATGTATGTGTG | p.Pro452_Cys453insValValTyrTerArgAsnValTyrValCysVal | p.P452_C453insVVY*RNVYVCV | Q8NFT2 | protein_coding | | | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD |
STEAP2 | insertion | Frame_Shift_Ins | rs755155219 | c.672_673insT | p.Leu228ProfsTer14 | p.L228Pfs*14 | Q8NFT2 | protein_coding | | | TCGA-D1-A17H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STEAP2 | SNV | Missense_Mutation | novel | c.865N>T | p.Arg289Trp | p.R289W | Q8NFT2 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-2Y-A9HA-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
STEAP2 | SNV | Missense_Mutation | novel | c.623T>A | p.Leu208His | p.L208H | Q8NFT2 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-05-4420-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |